AST2303 ，
Phase 1Small molecule
AST2303 ， is one of 3 small molecule programs targeting Locally Advanced or Metastatic Non-small Cell Lung Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Trastuzumab Deruxtecan
AstraZenecaPhase 3
AST2303 ，
AAllist Pharmaceuticals, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AST2303 ，. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAllist Pharmaceuticals, Inc.